Q1 Earnings Forecast for ImmunityBio Issued By HC Wainwright

ImmunityBio, Inc. (NASDAQ:IBRX - Free Report) - Stock analysts at HC Wainwright lowered their Q1 2025 earnings per share (EPS) estimates for ImmunityBio in a research note issued to investors on Wednesday, April 16th. HC Wainwright analyst A. Maldonado now anticipates that the company will post earnings of ($0.13) per share for the quarter, down from their prior estimate of ($0.12). HC Wainwright currently has a "Buy" rating and a $8.00 price target on the stock. The consensus estimate for ImmunityBio's current full-year earnings is ($0.92) per share. HC Wainwright also issued estimates for ImmunityBio's Q2 2025 earnings at ($0.13) EPS, Q3 2025 earnings at ($0.12) EPS, Q4 2025 earnings at ($0.12) EPS and FY2025 earnings at ($0.48) EPS.

ImmunityBio (NASDAQ:IBRX - Get Free Report) last released its quarterly earnings results on Monday, March 3rd. The company reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.26) by $0.11. The company had revenue of $7.55 million for the quarter, compared to analysts' expectations of $8.74 million.

A number of other equities research analysts have also issued reports on the company. D. Boral Capital reissued a "buy" rating and set a $30.00 price target on shares of ImmunityBio in a research note on Wednesday. BTIG Research assumed coverage on ImmunityBio in a report on Friday, January 10th. They issued a "buy" rating and a $6.00 target price for the company. One research analyst has rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average price target of $12.19.

ImmunityBio Price Performance

Shares of IBRX traded up $0.08 during midday trading on Friday, hitting $2.77. The stock had a trading volume of 3,974,698 shares, compared to its average volume of 5,807,634. ImmunityBio has a 1 year low of $2.28 and a 1 year high of $10.53. The stock's 50 day moving average is $2.92 and its 200 day moving average is $3.49. The firm has a market cap of $2.36 billion, a PE ratio of -3.01 and a beta of 0.51.

Hedge Funds Weigh In On ImmunityBio

Large investors have recently bought and sold shares of the business. State Street Corp boosted its stake in shares of ImmunityBio by 10.1% in the third quarter. State Street Corp now owns 8,654,460 shares of the company's stock worth $32,195,000 after acquiring an additional 790,408 shares during the last quarter. Barclays PLC lifted its stake in shares of ImmunityBio by 127.4% in the third quarter. Barclays PLC now owns 361,036 shares of the company's stock worth $1,344,000 after buying an additional 202,248 shares in the last quarter. Altium Capital Management LLC acquired a new position in ImmunityBio during the fourth quarter worth about $2,714,000. Vanguard Group Inc. grew its stake in ImmunityBio by 2.5% during the 4th quarter. Vanguard Group Inc. now owns 17,328,229 shares of the company's stock valued at $44,360,000 after acquiring an additional 425,713 shares in the last quarter. Finally, Handelsbanken Fonder AB raised its holdings in ImmunityBio by 71.2% in the 4th quarter. Handelsbanken Fonder AB now owns 92,300 shares of the company's stock valued at $236,000 after acquiring an additional 38,400 shares during the last quarter. Institutional investors and hedge funds own 8.58% of the company's stock.

ImmunityBio Company Profile

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.